Optimization of concomitant medication in Fabry cardiomyopathy

Acta Paediatrica, International Journal of Paediatrics

Volumn 96, Issue SUPPL. 455, 2007, Pages 81-83

  Close, Lydia ^a   Elliott, Perry ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Cardiomyopathy; Concomitant medication; Fabry disease

Indexed keywords

AMIODARONE; AMLODIPINE; BISOPROLOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SIMVASTATIN; SPIRONOLACTONE; WARFARIN;

ADULT; ANGIOCARDIOGRAPHY; CARDIOMYOPATHY; CARDIOVERSION; CASE REPORT; CONFERENCE PAPER; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; ENZYME REPLACEMENT; EXERCISE TOLERANCE; FABRY DISEASE; GENE MUTATION; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FLUTTER; HEART FAILURE; HEART GRAFT; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; LOW DRUG DOSE; MALE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; SYSTOLIC DYSFUNCTION; THORAX PAIN; THYROTOXICOSIS;

CARDIOVASCULAR AGENTS; FABRY DISEASE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED;

EID: 33947592550     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2007.00215.x     Document Type: Conference Paper

References (14)

1. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th edn. New York: McGraw-Hill; 2001: 3733-74.
2. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38: 769-75.
3. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38: 750-60.
4. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004; 34: 236-42.
5. Linhart A. The heart in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis Ltd; 2006: 180-201.
6. Elliott PM, Kindler H, Shah JS, Sachdev B, Rimoldi OE, Thaman R, et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 2006; 92: 357-60.
7. Kalliokoski RJ, Kalliokoski KK, Sundell J, Engblom E, Penttinen M, Kantola I, et al. Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease. J Inherit Metab Dis 2005; 28: 563-73.
8. Shah JS, Lee P, Hughes D, Thaman R, Sachdev B, Pellerin D, et al. The natural history of left ventricular systolic function in Anderson-Fabry disease. Heart 2005; 91: 533-4.
9. Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 2003; 107: 1978-84.
10. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003; 108: 1299-301.
11. Bradley DJ, Bradley EA, Baughman KL, Berger RD, Calkins H, Goodman SN, et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA 2003; 289: 730-40.
12. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-49.
13. Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, Lee P, et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 2005; 96: 842-6.
14. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-37.